Epigral Limited, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across various regions. Founded in 2015, the company has rapidly established itself as a leader in the development of innovative solutions for the pharmaceutical and healthcare industries. Specialising in advanced drug delivery systems and biopharmaceuticals, Epigral Limited is recognised for its unique approach to enhancing therapeutic efficacy and patient compliance. The company’s commitment to research and development has led to significant milestones, including collaborations with major healthcare institutions. With a strong market position, Epigral Limited continues to drive advancements in biotechnology, making substantial contributions to the global healthcare landscape. Its focus on quality and innovation sets it apart in a competitive industry, ensuring it remains at the forefront of biotechnological advancements.
How does Epigral Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Epigral Limited's score of 12 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Epigral Limited reported significant carbon emissions, totalling approximately 1,068,775,820 kg CO2e from Scope 1 and about 80,113,000 kg CO2e from Scope 2. The following year, 2024, emissions increased slightly, with Scope 1 emissions reaching about 1,150,906,590 kg CO2e, Scope 2 emissions at approximately 61,263,810 kg CO2e, and Scope 3 emissions from purchased goods and services contributing about 35,898,630 kg CO2e. Despite these figures, there are currently no publicly disclosed reduction targets or climate pledges from Epigral Limited. The absence of specific initiatives or commitments highlights a potential area for improvement in their climate strategy. As the company continues to operate within the global market, addressing its carbon footprint will be crucial for aligning with industry standards and expectations regarding climate action.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2023 | 2024 | |
---|---|---|
Scope 1 | 1,068,775,820 | 0,000,000,000 |
Scope 2 | 80,113,000 | 00,000,000 |
Scope 3 | - | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Epigral Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.